Patents by Inventor Keith R. Hildebrand
Keith R. Hildebrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090263448Abstract: Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.Type: ApplicationFiled: March 26, 2009Publication date: October 22, 2009Applicant: WARSAW ORTHOPEDIC, INC.Inventors: Christopher M. Hobot, Phillip E. McDonald, Keith R. Hildebrand
-
Publication number: 20090263319Abstract: Methods and compositions are provided for reducing, treating or preventing postoperative pain or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of ketorolac or pharmaceutically acceptable salt thereof to a target tissue site, wherein the drug depot releases an effective amount of ketorolac or pharmaceutically acceptable salt thereof over a period of 3 to 10 days.Type: ApplicationFiled: February 19, 2009Publication date: October 22, 2009Applicants: Warsaw Orthopedic, Inc., Medtronic Inc.Inventors: Amira Wohabrebbi, William F. McKay, Christopher M. Hobot, Keith R. Hildebrand, Edward Phillip McDonald
-
Publication number: 20090208554Abstract: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of baclofen formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.Type: ApplicationFiled: April 17, 2009Publication date: August 20, 2009Applicant: Medtronic, Inc.Inventors: Christopher M. Hobot, Michael E. Benz, Keith R. Hildebrand, Bryant J. Pudil
-
Publication number: 20090202604Abstract: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.Type: ApplicationFiled: April 17, 2009Publication date: August 13, 2009Applicant: Medtronic, Inc.Inventors: Christopher M. Hobot, Michael E. Benz, Keith R. Hildebrand, Bryant J. Pudil
-
Publication number: 20090202436Abstract: Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.Type: ApplicationFiled: April 17, 2009Publication date: August 13, 2009Applicant: Medtronic, Inc.Inventors: Christopher M. Hobot, Michael E. Benz, Keith R. Hildebrand, Bryant J. Pudil
-
Publication number: 20080228133Abstract: A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g.Type: ApplicationFiled: May 28, 2008Publication date: September 18, 2008Inventors: KEITH R. HILDEBRAND, Michael R. Ujhelyi, Xiaohong Zhou, Daniel C. Sigg, Linda M. Page
-
Patent number: 7390311Abstract: A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g.Type: GrantFiled: July 30, 2004Date of Patent: June 24, 2008Assignee: Medtronic, Inc.Inventors: Keith R. Hildebrand, Michael R. Ujhelyi, Xiaohong Zhou, Daniel C. Sigg, Linda M. Page
-
Patent number: 7232435Abstract: A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g.Type: GrantFiled: February 6, 2004Date of Patent: June 19, 2007Assignee: Medtronic, Inc.Inventors: Keith R. Hildebrand, Michael R. Ujhelyi, Xiaohong Zhou, Daniel C. Sigg, Linda M. Page
-
Patent number: 7169812Abstract: Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic when administered intrathecally. Thus, heating for the purposes of sterilization or to assure sterility provides a viable option in the production of injectable compositions containing gabapentin.Type: GrantFiled: March 24, 2004Date of Patent: January 30, 2007Assignee: Medtronic, Inc.Inventors: Keith R. Hildebrand, Linda M. Page, Deanna S. Lane, Dennis D. Elsberry, David A. Clarahan, Jayantha H. Ratnayake
-
Patent number: 6139538Abstract: An apparatus for iontophoretically delivering an agent to a patient having a uterus and a cervix. The apparatus comprises a probe sized to fit within the cervical canal. A cervical cap has an inner surface. The probe projects from the inner surface. A first electrode has a first portion operably connected to the cervical cap and a second portion operably connected to the probe. The first electrode is configured to be electrically connected to a power supply. A second electrode is configured to be electrically connected to the power supply. A reservoir having a first portion operably connected to the cervical cap and a second portion operably connected to the probe.Type: GrantFiled: October 6, 1997Date of Patent: October 31, 2000Assignee: Iotek, Inc.Inventors: William C. Houghton, Keith R. Hildebrand, Martin B. Finkelstein, Frederick J. Foley
-
Patent number: 5865787Abstract: An apparatus and method for delivering a drug selectively and locally to internal body tissue with a catheter using electric current/voltage controlled in conjunction with active pacing of cardiac activity.Type: GrantFiled: September 13, 1996Date of Patent: February 2, 1999Assignee: Cortrak Medical, Inc.Inventors: James E. Shapland, Keith R. Hildebrand
-
Patent number: 5861431Abstract: The present invention provides a method of treating incontinence in a patient that has a bladder and a urethra. The urethra forms a lumen for draining the bladder. The method comprises the steps of delivering an agent into the lumen and passing the agent from the lumen to internal body tissue. The agent increases restriction of the lumen thereby providing increased control over urine flow from the bladder.Type: GrantFiled: June 7, 1995Date of Patent: January 19, 1999Assignee: Iotek, Inc.Inventors: Keith R. Hildebrand, Jan Ellen O. Fowler, Dezso K. Levius
-
Patent number: 5749845Abstract: A method of delivering an agent to an organ from the group consisting of a bladder or a uterus. The method utilizes a catheter having an inflatable portion. The inflatable portion of the catheter is inserted into the organ and is inflated so that it expands the organ. The agent is then delivered from the inflatable portion into the wall of the organ. The agent may be prevented from escaping the organ.Type: GrantFiled: January 25, 1995Date of Patent: May 12, 1998Assignee: Iotek, Inc.Inventors: Keith R. Hildebrand, J. Edward Shapland
-
Patent number: 5634899Abstract: An apparatus and method for delivering a drug selectively and locally to internal body tissue with a catheter using electric current/voltage controlled in conjunction with active pacing of cardiac activity.Type: GrantFiled: January 4, 1994Date of Patent: June 3, 1997Assignee: CorTrak Medical, Inc.Inventors: James E. Shapland, Keith R. Hildebrand
-
Patent number: 5458568Abstract: A drug delivery apparatus and method for delivering a drug locally to internal body tissue. The invention contemplates positioning a drug delivery device in a body passageway or within body tissue and then selectively wetting a membrane within the device, making the membrane permeable and allowing transport of a drug across the membrane and into the passageway wall or body tissue.Type: GrantFiled: September 17, 1993Date of Patent: October 17, 1995Assignee: CorTrak Medical, Inc.Inventors: Joel R. Racchini, James E. Shapland, Mark B. Knudson, Jin Shimada, Keith R. Hildebrand
-
Patent number: 5419763Abstract: A method and apparatus for the treatment of a prostate gland which isolates the prostatic urethra from the membranous urethra and the bladder so that fluid may be transported into the prostatic ducts without compromising the openings to the prostatic ducts. One preferred embodiment incorporates balloons located at either end of the prostatic urethra to isolate the same.Type: GrantFiled: January 4, 1994Date of Patent: May 30, 1995Assignee: CorTrak Medical, Inc.Inventor: Keith R. Hildebrand
-
Patent number: 5282785Abstract: A drug delivery apparatus and method for delivering a drug locally to internal body tissue. The invention contemplates positioning a drug delivery device in a body passageway or within body tissue and then selectively introducing a selected drug so that it is transported across a drug transport wall of the device for direct contact with the passageway wall or body tissue. A further aspect of the present invention involves treating a dilated vessel in the area of a stenotic lesion with a fixative or other drug to render the vessel biologically inert and to form a biological stent or prevent restenosis using specifically selected drugs. A still further aspect of the present invention involves treating a tumor or local or regional tissue mass with antitumor sensitizing agents, biological modifiers, antibiotics or other types of drugs by delivery of the drug to the tumor or tissue area directly or through the passageway wall.Type: GrantFiled: October 5, 1992Date of Patent: February 1, 1994Assignee: CorTrak Medical, Inc.Inventors: James E. Shapland, Mark B. Knudson, Jin Shimada, Keith R. Hildebrand